Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer

Tonyali, Onder; Coskun, UĞUR; Sener, Nur; İNANÇ, MEVLÜDE; Akman, Tulay; Oksuzoglu, Berna; Ozdemir, Nuriye; Yazilitas, Dogan; Benekli, Mustafa; ÜNER, AYTUĞ; Yamac, Deniz; Demirci, Umut; Yildiz, Ramazan; Karaca, Halit; Unal, Olcun; Bal, Oznur; Gumus, Mahmut; Buyukberber, Suleyman

doi:10.1007/s00432-012-1296-x

Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer

Copy For Citation

Tonyali O., Coskun U., Sener N., İNANÇ M., Akman T., Oksuzoglu B., ...More

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.138, no.12, pp.2145-2151, 2012 (SCI-Expanded)

Publication Type: Article / Article
Volume: 138 Issue: 12
Publication Date: 2012
Doi Number: 10.1007/s00432-012-1296-x
Journal Name: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.2145-2151
Keywords: Trastuzumab, Adjuvant therapy, Breast cancer, HER2, PLUS ADJUVANT CHEMOTHERAPY, DOCETAXEL, ONCOGENE
Gazi University Affiliated: Yes

Abstract

Purposes Trastuzumab is known to be effective for early and advanced stages of breast cancer but optimal duration for early-stage breast cancer (EBC) is not well known. We evaluated the efficacy and toxicity of 9- and 52-week trastuzumab therapy for EBC retrospectively.